The efficacy of auger and internal conversion electron emission 0f in-111 to treat neuroendocrine tumors
Somatostatin
Gastro-entero-pancreatic neuroendocrine tumors
[111in-dtpa0-d-phe1]
octreotide: the ligand -the receptor-label
Regulations and requirements of hospitals performing radio-infusions
Intravenous radio-peptide infusion with in-octreotide
Intra-arterial radio-peptide infusion
Radio-peptide infusions after implementation of an intra-arterial port system
US, CT and MRI for the evaluation of patients with neuroendocrine tumors
Angiographic anatomy on the course of liver intra-arterial infusion
Liver radio-infusions: identifying anatomic variants
Dosimetry and dose calculation: its necessity in radio-peptide therapy
Evaluation and assessment of the radio-peptide treatment efficacy
Intra-venous radio-peptide infusions with in-octreotide for the treatment of bronchial carcinoids
Intra-arterial radio
peptide infusions for the treatment of colorectal carcinomas
Intra-arterial radio-peptide infusions for the treatment of paragangliomas
Intra-arterial radio-peptide infusions for the treatment of brain meningiomas
Surgery in neuroendocrine tumors
Cytoreductive surgery combined with intraperitoneal [111in-dtpa0 d-phe1]-octreotide infusions in neuroendocrine character metastases
Patients survival followed intra-arterial versus intravenous infusions
Complications and side effects on the course of liver-radio-infusions
Progression free survival and response rate in neuroendocrine liver metastasized patients, treated with in-111 octreotide
Therapy response vs variability of tumor size, absorbed dose, and ki-67 index after in-111 octreotide intra-arterial infusions.